Physician-led
Therapy begins and remains with the treating physician.
Therapeutic franchise
Cannabinoid-based medicine, held to pharmaceutical standard
Cannexa is the cannabinoid-based medical products franchise of Altanova Pharma Group AG, focused on chronic disease areas where cannabinoid-based therapies are already prescribed under medical supervision and the evidence base continues to grow.
5 therapeutic areas
Chronic disease states with a defined and growing evidence base, described at disease-state level.
4 format classesEstablished pharmaceutical delivery formats, described generically and defined per product.
1 regulated channelThe licensed Swiss medical channel only, with strict separation from any non-medical market.
The franchise thesis
Cannabinoid science, applied to chronic disease
Cannabinoids interact with receptor systems found throughout the body, which is why research spans a wide range of chronic conditions. Research activity is concentrated in conditions managed over years, where continuity of care and consistent supply matter as much as the therapy itself.
Access to these therapies remains fragmented across much of Europe: pathways vary by market, supply can be inconsistent, and prescribers carry the burden of navigating both. Cannexa exists to bring structure to that problem.
Standardised supply
Defined inputs, complete characterisation, one specification.
Evidence loop
Consent-based outcomes data feeding back into practice.
The specification argument
Botanical variability is incompatible with pharmaceutical practice, so the work of the franchise is to engineer that variability out: defined inputs, complete characterisation and a specification a batch must meet before it reaches a patient.
Delivery formats
Format follows the clinical need
Route of administration shapes onset, duration and the reproducibility a format must meet. Each is described here generically, as a class.
Oral
Swallowed formats pass through first-pass metabolism, so onset is gradual and duration extended, the profile that suits therapy taken to a steady schedule. Reproducibility depends on a standardised matrix and a validated release profile.
Gradual onsetExtended durationValidated release
Sublingual
Absorption through the mucosa reaches the circulation ahead of first-pass metabolism, giving a faster and more direct onset than a swallowed format. Reproducibility depends on precise concentration control per administered volume.
Faster onsetPre-systemic absorptionConcentration control
Transdermal
Delivery through the skin holds exposure steady across an extended wear period without repeated administration, flattening the peaks and troughs of intermittent dosing. Reproducibility depends on validated release-rate control across the whole wear time.
Continuous deliveryExtended wearRelease-rate control
Topical
Applied directly to the site, a topical preparation is formulated for local delivery with systemic exposure kept low by design. Reproducibility depends on defined concentration, a stable base, and consistent release from that base.
Local applicationLow systemic exposureDefined stability
Specific products and formats are defined per development programme, and only as authorisations permit. No format described here is an assertion that a corresponding product exists.
How the franchise works
Three disciplines, held constantly
Specification first
Cannexa exists so that no batch reaches a patient until it has been tested against its written specification and released.
Evidence before expansion
Cannexa works only where the published evidence is already established and growing, and says so plainly where that evidence is thin or points both ways.
Exact status
Cannexa describes every licence, authorisation and appointment exactly as it stands, planned, filed or granted, never further along than it is.
Our partners
Avicanna Inc. (TSX: AVCN) is a strategic partner of Altanova Pharma Group AG.
The access model
Prescriber, pharmacy, patient
Access is the practical bottleneck for physicians and pharmacies across much of Europe. The franchise describes that structure openly, as a pathway, never as a product.
Prescription
Therapy begins with the treating physician, who directs it throughout. The franchise supports that decision with education and structured, non-promotional information.
Pharmacy dispensing
Dispensing runs through licensed Swiss pharmacies, with pharmacist review of every prescription and the documentation that controlled products require.
Patient support
Support across the course of therapy is delivered as pharmacy patient services through the licensed channel: continuity, adherence and pharmacist follow-up.
Structured follow-up
With patient consent, structured outcomes data supports the physician’s clinical picture over time and feeds the Group’s evidence loop.
Therapeutic areas
All therapeutic areasWhere the franchise focuses
Regulatory framing
Inside the regulated medical channel, exactly
The BetmG framework
The manufacture, distribution and dispensing of controlled substances in Switzerland are governed by the Federal Act on Narcotic Drugs (BetmG) and the Narcotics Control Ordinance (BetmKV). The franchise operates within that framework.
Strict separation
Cannexa works exclusively in the regulated medical channel, as the BetmG framework requires. Strict separation of sourcing, branding, channels and conduct from any non-medical market is standing policy.
Gated product information
Product-level information is available only to healthcare professionals who have confirmed their status. Nothing on this page describes a product.
Cannexa products are not offered for sale through this website. Product information will be published only when permitted and appropriate to the intended audience. Medicines are dispensed exclusively through licensed Swiss pharmacies on a physician’s prescription.